Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119

Sort by

Sort Order Select

Journal Articles

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

Blood (2025) 146 (Supplement 1): 3862.

https://doi.org/10.1182/blood-2025-3862

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Blood (2025) 146 (Supplement 1): 490.

https://doi.org/10.1182/blood-2025-490

Published: 2025

Journal Articles

Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)

David Swoboda, Amy DeZern, James England, Sangeetha Venugopal, Thomas Kehoe, Brandon Aubrey, Marco Gabriele Raddi, Angela Consagra, Jiasheng Wang, Gustavo Rivero, Maximilian Stahl, Amer Zeidan, Torsten Haferlach, Andrew Brunner, Rena Buckstein, Valeria Santini, Matteo Della Porta, Mikkael Sekeres, Aziz Nazha

Blood (2025) 146 (Supplement 1): 7363.

https://doi.org/10.1182/blood-2025-7363

Published: 2025

Journal Articles

Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications

Blood (2025) 146 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2025-4349

Published: 2025

Journal Articles

Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus

Blood (2025) 146 (Supplement 1): 789.

https://doi.org/10.1182/blood-2025-789

Published: 2025

Journal Articles

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

Blood (2025) 146 (Supplement 1): 964.

https://doi.org/10.1182/blood-2025-964

Published: 2025

Journal Articles

How I treat iron overload in adult MDS

Heather A. Leitch, Rena Buckstein

Blood (2025) 145 (4): 383–396.

https://doi.org/10.1182/blood.2023022501

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Blood (2024) 144 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2024-211183

Published: 2024

Journal Articles

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 3228.1.

https://doi.org/10.1182/blood-2024-200797

Published: 2024

Journal Articles

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Blood (2024) 144 (Supplement 1): 4583.

https://doi.org/10.1182/blood-2024-194441

Published: 2024

Journal Articles

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2024-203274

Published: 2024

Journal Articles

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 352.

https://doi.org/10.1182/blood-2024-203612

Published: 2024

Journal Articles

A Hgb Exceeding 120g/L Does Not Increase Risk of Vascular Complications or Disease Progression in Patients with MDS Treated with Erythropoietic Stimulating Agents, a Single-Institution Retrospective Study of the MDS-CAN Registry

Clarissa Skorupski, Lisa Chodirker, Lee Mozessohn, James T England, James Kennedy, Matthew C. Cheung, Signy Chow, Jennifer Teichman, Nicola Goldberg, Samantha A. Hershenfeld, Hubert Tsui, Mohammed Siddiqui, Alexandre Mamedov, Liying Zhang, Rena Buckstein

Blood (2024) 144 (Supplement 1): 6716.

https://doi.org/10.1182/blood-2024-209053

Published: 2024

Journal Articles

Mutational and Clinical Characteristics Associated with Atherosclerotic Disease Burden in the MDS Canada Database: A Single-Center Analysis of CT Coronary Artery Calcium Scores

Arjun Pandey, Idan Roifman, Bo Wan, Tara Williams, James Kennedy, Signy Chow, Lee Mozessohn, Lisa Chodirker, Alexandre Mamedov, Iran Rashedi, Mohammed Siddiqui, Rashmi S. Goswami, Rena Buckstein

Blood (2024) 144 (Supplement 1): 6715.

https://doi.org/10.1182/blood-2024-208203

Published: 2024

Journal Articles

Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Troy Climans, Camilla Zimmermann, Annette E. Hay, Harriet Richardson, Pierre Villeneuve, Lee Mozessohn, Andre C. Schuh, Janique Dyba, Breffni Hannon, David Lee, Rena Buckstein, Argin Malakian, Kyle Fitzgibbon, Joel Lefebvre, Wei Tu, Gary Rodin

Blood (2023) 142 (Supplement 1): 1494.

https://doi.org/10.1182/blood-2023-174378

Published: 2023

Journal Articles

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Valeria Santini, Rami S. Komrokji, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Karen L. Keeperman, Shelonitda Rose, Ana Carolina Giuseppi, Valerie Vilmont, Yinzhi Lai, Dimana Miteva, Barkha Aggarwal, Uwe Platzbecker, Pierre Fenaux, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 915.

https://doi.org/10.1182/blood-2023-178546

Published: 2023

Journal Articles

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Rena Buckstein, Olivia Lopes, Amy J. M. McNaughton, Matthew C. Cheung, Lee Mozessohn, Lisa Chodirker, Kevin Imrie, Neil Berinstein, Signy Chow, Gillian Kupakuwana-Suk, Anne Parmentier, Prasha Sasitharakumar, Hubert Tsui, Liying Zhang, Michael J. Rauh

Blood (2023) 142 (Supplement 1): 442.

https://doi.org/10.1182/blood-2023-187778

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A comparison of overall survival and quality of life in MDS patients treated with azacytidine vs decitabine: A propensity matched registry Study

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)

Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications

Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus

Grip strength predicts overall survival of patients with myelodysplastic syndrome in a multivariable model

How I treat iron overload in adult MDS

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

A Hgb Exceeding 120g/L Does Not Increase Risk of Vascular Complications or Disease Progression in Patients with MDS Treated with Erythropoietic Stimulating Agents, a Single-Institution Retrospective Study of the MDS-CAN Registry

Mutational and Clinical Characteristics Associated with Atherosclerotic Disease Burden in the MDS Canada Database: A Single-Center Analysis of CT Coronary Artery Calcium Scores

Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only